Drugs / Belantamab mafodotin
Belantamab mafodotin
also known as
GSK2857916 · belamaf · Blenrep · Belantamab mafodotin blmf · Belantamab mafodotina · Belantamab mafodotine
Monoclonal antibody targets TNFRSF17
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved · conditional | EU (EMA) | Blenrep | — | 2020-08-25 | europa.eu ↗ |
Trials 67 · started per year
today
EU approved 2020
1
1
3
8
6
15
13
5
5
2
7
20152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT07609706 | Oct 2026 → Aug 2031 expected | plasma cell myeloma | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05065047 | Jan 2023 → Nov 2025 | plasma cell myeloma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT05556798 | Oct 2022 → Oct 2026 expected | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05055063 | May 2022 → Feb 2027 expected | plasma cell myeloma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04892264 | Jun 2021 → Mar 2024 | plasma cell myeloma | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT04398680 | Apr 2021 → Nov 2025 | plasma cell myeloma | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 1 | NCT04398745 | Oct 2020 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04091126 | Dec 2019 → Jun 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04177823 | Dec 2019 → Dec 2021 | plasma cell myeloma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT03828292 | Mar 2019 → Apr 2023 | plasma cell myeloma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02064387 | Jul 2014 → Aug 2018 | plasma cell myeloma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/228 trials | ||||||
| Phase 1/2 | NCT07612787 | Jun 2026 → Jan 2028 expected | plasma cell myeloma | University Hospital of Saint-Etienne | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06232044 | Apr 2025 → May 2028 expected | plasma cell myeloma | Alliance for Clinical Trials in Oncology | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05145816 | Feb 2024 → Mar 2027 expected | AL amyloidosis | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05573802 | Jul 2023 → Oct 2026 expected | corneal disorder, monoclonal paraproteinemia disease, plasma cell myeloma | Hellenic Society of Hematology | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05853965 | Jun 2023 → Apr 2027 expected | plasma cell myeloma | University Medical Center Hamburg-Eppendorf | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05714839 | Jun 2023 → Aug 2028 expected | plasma cell myeloma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05493618 | Dec 2022 → Nov 2025 | plasma cell myeloma | Hackensack Meridian Health | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05581875 | Oct 2022 → Oct 2026 expected | corneal disorder, monoclonal paraproteinemia disease, plasma cell myeloma | Hellenic Society of Hematology | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07150104 | Aug 2022 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT07150091 | Jul 2022 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05280275 | Apr 2022 → Mar 2026 | corneal disorder, monoclonal paraproteinemia disease, plasma cell myeloma | Hellenic Society of Hematology | Unknown | No outcome recorded |
| Phase 1/2 | NCT05002816 | Feb 2022 → Jan 2026 overdue | plasma cell myeloma | Yale University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05060627 | Dec 2021 → Oct 2024 overdue | plasma cell myeloma | PETHEMA Foundation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04896658 | Dec 2021 → Jun 2023 | refractory plasma cell neoplasm | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 1/2 | NCT07217184 | Jul 2021 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04822337 | May 2021 → Apr 2029 expected | plasma cell myeloma | Wake Forest University Health Sciences | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06655818 | Mar 2021 → Feb 2024 | refractory plasma cell neoplasm | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1/2 | NCT04808037 | Feb 2021 → Sep 2028 expected | plasma cell myeloma | Hellenic Society of Hematology | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04643002 | Jan 2021 → Sep 2027 expected | plasma cell myeloma | Sanofi | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07084896 | Jun 2020 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT07217119 | Nov 2019 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04126200 | Oct 2019 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06160609 | Oct 2019 → Jan 2023 | refractory plasma cell neoplasm | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1/2 | NCT03732703 | Apr 2019 → Dec 2024 | refractory plasma cell neoplasm | Multiple Myeloma Research Consortium | Completed | No outcome recorded |
| Phase 1/2 | NCT03848845 | Mar 2019 → Oct 2021 | plasma cell myeloma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT03715478 | Nov 2018 → Jun 2025 overdue | refractory plasma cell neoplasm | Canadian Myeloma Research Group | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03544281 | Sep 2018 → Feb 2023 | plasma cell myeloma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT02343042 | Oct 2015 → Apr 2027 expected | plasma cell myeloma | Karyopharm Therapeutics Inc | Recruiting | No outcome recorded |
| Phase 218 trials | ||||||
| Phase 2 | NCT07614360 | Aug 2026 → Feb 2029 expected | plasma cell myeloma | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07224672 | Jun 2026 → Jan 2033 expected | AL amyloidosis | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 2 | NCT05874193 | May 2026 → May 2028 expected | refractory plasma cell neoplasm | Cristiana Costa Chase, DO | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07227311 | Apr 2026 → Aug 2030 expected | plasma cell myeloma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 2 | NCT07019545 | Jun 2025 → Jun 2026 overdue | autoimmune thrombocytopenia | Hellenic Society of Hematology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04876248 | Aug 2024 → Sep 2026 expected | plasma cell myeloma | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05922501 | May 2024 → Dec 2028 expected | plasma cell myeloma | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05847569 | Jan 2024 → Jun 2029 expected | plasma cell myeloma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT05789303 | May 2023 → Jul 2028 expected | plasma cell myeloma | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT05091372 | Dec 2022 → Dec 2027 expected | plasma cell myeloma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05208307 | Jul 2022 → Oct 2026 expected | plasma cell myeloma | Emory University | Recruiting | No outcome recorded |
| Phase 2 | NCT05117008 | Jul 2022 → Jan 2024 | refractory plasma cell neoplasm | Medical College of Wisconsin | Terminated | No outcome recorded |
| Phase 2 | NCT05064358 | Mar 2022 → Aug 2024 | plasma cell myeloma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT04676360 | Jul 2021 → Nov 2023 | ALK-positive large B-cell lymphoma, plasmablastic lymphoma | Jacob Soumerai, MD | Terminated | No outcome recorded |
| Phase 2 | NCT04680468 | Jun 2021 → Jul 2026 overdue | plasma cell myeloma | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04802356 | Apr 2021 → Mar 2025 overdue | plasma cell myeloma | PETHEMA Foundation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04617925 | Feb 2021 → Jul 2025 | AL amyloidosis | Stichting European Myeloma Network | Completed | No outcome recorded |
| Phase 2 | NCT03525678 | Jun 2018 → Jun 2019 | plasma cell myeloma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT07285239 | Jul 2026 → Nov 2031 expected | plasma cell myeloma | PrECOG, LLC. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06679101 | Dec 2024 → Apr 2031 expected | plasma cell myeloma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06956170 | Feb 2022 → May 2024 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06868667 | Jul 2021 → Apr 2024 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06868654 | Jul 2021 → Apr 2024 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04549363 | Dec 2020 → Nov 2022 | plasma cell myeloma | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 3 | NCT04484623 | Oct 2020 → Jan 2024 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04246047 | May 2020 → Oct 2023 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04162210 | Apr 2020 → Sep 2022 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03763370 | — | plasma cell myeloma | GlaxoSmithKline | Available | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05461209 Comparator | Oct → Nov 2022 | refractory plasma cell neoplasm | Janssen Research & Development, LLC | Withdrawn | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 78 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Belantamab mafodotin | “The two-part ALGONQUIN trial evaluated various doses and schedules of the anti-BCMA antibody-drug conjugate belantamab mafodotin plus pomalidomide and dexamethasone for...” PMID 38177852 ↗ Jan 202468“Belantamab mafodotin was approved by the U.S. Food and Drug Administration (FDA) on Aug 5, 2020, for treating patients with relapsed/refractory multiple myeloma.” NCT04896658 ↗ “A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma” NCT07612787 ↗ “Belantamab-Mafodotin 1.9 mg/kg day 1, Q8W” NCT05060627 ↗ “Biological: Belantamab Mafodotin” NCT04876248 ↗ |
| Known as | belamaf | “The phase 1/2 BelaRd (belantamab mafodotin [belamaf], lenalidomide, and dexamethasone) study evaluated the efficacy and safety of belamaf combined with lenalidomide and...” PMID 41346230 ↗ Apr 20265“Belantamab mafodotin (belamaf) combined with standard therapies demonstrated significant progression-free survival (PFS) and overall survival benefits in DREAMM-7 and PFS...” PMID 40763276 ↗ Nov 2025 “Belantamab mafodotin (belamaf), an antibody-drug conjugate targeting B-cell maturation antigen, has demonstrated single-agent activity in relapsed/refractory multiple myeloma...” PMID 41719502 ↗ May 2026 “Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have...” PMID 33682447 ↗ Mar 2021 “Belantamab mafodotin (belamaf; GSK2857916) is a first-in-class antibody-drug conjugate (ADC; or immunoconjugate) that delivers a cytotoxic payload, monomethyl auristatin F...” PMID 32712806 ↗ Jul 2020 “Belantamab mafodotin (belamaf) has shown promising antimyeloma activity in relapsed or refractory multiple myeloma (RRMM) as a single agent.” PMID 38630908 ↗ Apr 2024 |
| Known as | Belantamab mafodotin blmf | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298209 ↗ |
| Known as | Belantamab mafodotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298209 ↗ |
| Known as | Belantamab mafodotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298209 ↗ |
| Known as | Blenrep | “belantamab mafodotin (Blenrep) can help to prevent multiple myeloma (MM) from coming back after patients have had an autologous stem cell transplant (AutoSCT).” NCT05065047 ↗1“Belantamab mafodotin (BLENREP) was approved in the US in August 2020 under an FDA program called accelerated approval.” NCT05874193 ↗ |
| Known as | GSK2857916 | “Belantamab mafodotin (GSK2857916) is a first in class, antibody dependent cellular cytotoxicity (ADCC) enhanced, humanized immunoglobulin G1 (IgG1) antibody-drug conjugate...” NCT03828292 ↗10“Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated...” PMID 31859245 ↗ Dec 2019 “Belantamab mafodotin (GSK2857916) is an antibody-drug conjugate (ADC) comprised of an afucosylated, humanized Immunoglobulin G1 (IgG1) monoclonal immunoconjugate that binds...” NCT03763370 ↗ “Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma” NCT06232044 ↗ “Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin (GSK2857916)” NCT04549363 ↗ “belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA)” NCT04680468 ↗ “the Antibody Drug Conjugate GSK2857916 in Chinese Participants” NCT04177823 ↗ “Belantamab Mafodotin (GSK2857916) as Monotherapy” NCT04126200 ↗ “Belantamab Mafodotin (GSK2857916)” NCT05064358 ↗ |
| Action | Deplete | “Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action.” PMID 33682447 ↗ Mar 2021 |
| Modality | Monoclonal antibody | “a novel afucosylated anti-BCMA monoclonal antibody conjugated with monomethyl auristatin F via noncleavable linker (GSK2857916)” PMID 26370838 ↗ Sep 2015 |
| Route | Intravenous | “Participants will receive GSK2857916 intravenously over 60 minutes” NCT02064387 ↗ |
| Target | TNFRSF17 | “Tumor necrosis factor receptor superfamily member 17 binding agent” CHEMBL4298209 ↗ |